In the prostate cancer cell line LNCaP, WNT3A treatment can promote AR binding to the promoter regions of WNT target genes such as MYC and CYCLIN D1; additionally, AR and β-catenin can be recruited to the promoter and enhancer regions of the AR target gene PSA [35]. Here, AR is linked to Familial prostate cancer.